Pamela Conley

Pamela Conley has extensive work experience in the field of biotechnology. Pamela is currently the Chief Scientific Officer and Co-founder of Nuvig Therapeutics Inc., a position they have held since January 2023. Prior to this role, they served as the Chief Executive Officer and Co-founder of Nuvig Therapeutics Inc. from January 2022 to January 2023. Before Nuvig Therapeutics, they co-founded and served as the Chief Executive Officer of a stealth mode startup company in the biotech industry from November 2021 to May 2022.

Pamela has also worked at Portola Pharmaceuticals, where they held various roles. Pamela was a Senior Vice President from April 2017 to December 2020, Vice President of Biology from June 2013 to April 2017, and a Consultant in January 2013. Prior to Portola Pharmaceuticals, Pamela worked at iPierian as the Vice President of Research from April 2012 to December 2012.

Pamela'searlier experience includes roles at Portola Pharmaceuticals as the Vice President of Research Biology from September 2003 to May 2012, Millennium Pharmaceuticals as the Director of Biology from January 2001 to November 2003, and Cor Therapeutics as a Sr Scientist II/Project Leader from 1991 to 2001. Pamela began their career as a Postdoctoral fellow at Stanford University from 1989 to 1991.

Overall, Pamela Conley's work experience showcases their leadership roles in both established biotech companies and startup ventures, as well as their expertise in scientific research and project leadership.

Pamela Conley's education history includes a Bachelor of Arts degree in Biochemistry from The University of Texas at Austin, which they obtained from 1972 to 1976. Pamela then pursued further education at the University of California, Berkeley, where they earned their Ph.D. in Biochemistry from 1977 to 1983. Finally, they attended Stanford University from 1983 to 1991, where they completed a postdoctoral degree in Gene Expression in Procaryotic and Eukaryotic cells.